VIP is a 28-amino-acid neuropeptide with widespread distribution across the central and peripheral nervous systems. Research spans anti-inflammatory signaling, circadian clock regulation, and neuroprotection.
Category Archives: Peptides
FOXO4-DRI is a cell-penetrating peptide that selectively disrupts the FOXO4-p53 interaction in senescent cells. Published research in murine models showed restoration of multiple aging phenotypes.
Kisspeptin (KISS1) is a neuropeptide that serves as the master upstream regulator of the hypothalamic-pituitary-gonadal axis. It has become a critical tool in reproductive endocrinology research.
LL-37 is the only human cathelicidin-derived antimicrobial peptide, with broad-spectrum activity against bacteria, viruses, and biofilms. Research explores its dual role in direct antimicrobial action and immune system modulation.
An exploration of how AI and machine learning are transforming peptide research — from AlphaFold protein structure prediction to RFdiffusion generative design and QSAR modeling, plus limitations researchers must understand.
A detailed scientific comparison of GHRP-2 and GHRP-6, two ghrelin-receptor-targeting GH secretagogues. Covers GHS-R1a pharmacology, selectivity differences, hunger pathway involvement, and GHRH synergy.
A scientific exploration of oral peptide delivery challenges — enzymatic degradation, mucosal permeation barriers, and cutting-edge delivery strategies including nanoparticles, SNAC permeation enhancers, and structural modifications.
A scientific examination of clenbuterol as a research compound — covering β2-AR pharmacology, thermogenic cAMP/PKA/HSL cascade, skeletal muscle anabolic signaling in animal models, and cardiac hypertrophy research.
A comprehensive research overview of epitalon (Ala-Glu-Asp-Gly), a synthetic tetrapeptide studied for telomerase activation, pineal-hypothalamic axis modulation, and aging biomarker research.
A deep-dive into retatrutide (LY3437943), the triple agonist targeting GLP-1R, GIPR, and GCGR. Covers the glucagon receptor paradox, Phase II efficacy data (~24% body weight reduction), and pharmacodynamics.






